Hospira enters angry-investor phase of remediation

Hospira ($HSP) shareholders claim the company didn't disclose the extent of problems at its North Carolina plant. Yet CEO Michael Ball admitted in October 2011 that the remediation job was "bigger than we thought." Nonetheless, the ailing generics-maker is now dealing with class action lawsuits over what it didn't mention about GMP problems while crowing about its efficiency and cost-cutting program. Hospira is in good company: Johnson & Johnson ($JNJ), Genzyme and Caraco each faced investor lawsuits along their remediation journeys. Story

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.